These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32940533)

  • 1. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression and Replacement Gene Therapy for
    Bains S; Zhou W; Dotzler SM; Martinez K; Kim CJ; Tester DJ; Ye D; Ackerman MJ
    Circ Genom Precis Med; 2022 Dec; 15(6):e003719. PubMed ID: 36252106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Mehta A; Ramachandra CJA; Singh P; Chitre A; Lua CH; Mura M; Crotti L; Wong P; Schwartz PJ; Gnecchi M; Shim W
    Eur Heart J; 2018 Apr; 39(16):1446-1455. PubMed ID: 29020304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2.
    Mura M; Mehta A; Ramachandra CJ; Zappatore R; Pisano F; Ciuffreda MC; Barbaccia V; Crotti L; Schwartz PJ; Shim W; Gnecchi M
    Int J Cardiol; 2017 Aug; 240():367-371. PubMed ID: 28433559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome sequencing in a genetically elusive multigenerational long QT syndrome pedigree identifies a novel LQT2-causative deeply intronic KCNH2 variant.
    Tobert KE; Tester DJ; Zhou W; Haglund-Turnquist CM; Giudicessi JR; Ackerman MJ
    Heart Rhythm; 2022 Jun; 19(6):998-1007. PubMed ID: 35144019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2
    Ono M; Burgess DE; Schroder EA; Elayi CS; Anderson CL; January CT; Sun B; Immadisetty K; Kekenes-Huskey PM; Delisle BP
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32759882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
    Crotti L; Neves R; Dagradi F; Musu G; Giannetti F; Bos JM; Barbieri M; Cerea P; Giovenzana FLF; Torchio M; Mura M; Gnecchi M; Conte G; Auricchio A; Sala L; Odening KE; Ackerman MJ; Schwartz PJ
    Circulation; 2024 Aug; 150(7):531-543. PubMed ID: 38939955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
    Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
    Anderson CL; Delisle BP; Anson BD; Kilby JA; Will ML; Tester DJ; Gong Q; Zhou Z; Ackerman MJ; January CT
    Circulation; 2006 Jan; 113(3):365-73. PubMed ID: 16432067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of
    Zhou W; Ye D; Tester DJ; Bains S; Giudicessi JR; Haglund-Turnquist CM; Orland KM; January CT; Eckhardt LL; Maginot KR; Ackerman MJ
    Circ Genom Precis Med; 2023 Apr; 16(2):e003726. PubMed ID: 37071726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
    Smith JL; Reloj AR; Nataraj PS; Bartos DC; Schroder EA; Moss AJ; Ohno S; Horie M; Anderson CL; January CT; Delisle BP
    Am J Physiol Cell Physiol; 2013 Nov; 305(9):C919-30. PubMed ID: 23864605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG Channels.
    Campagna N; Wall E; Lee K; Guo J; Li W; Yang T; Baranchuk A; El-Diasty M; Zhang S
    Mol Pharmacol; 2023 Oct; 104(4):164-173. PubMed ID: 37419691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation reinitiation in c.453delC frameshift mutation of KCNH2 producing functional hERG K+ channels with mild dominant negative effect in the heterozygote patient-derived iPSC cardiomyocytes.
    Park NK; Park SJ; Park YG; Moon SH; Woo J; Kim HJ; Kim SJ; Choi SW
    Hum Mol Genet; 2024 Jan; 33(2):110-121. PubMed ID: 37769355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
    Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
    Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C.
    Delisle BP; Anderson CL; Balijepalli RC; Anson BD; Kamp TJ; January CT
    J Biol Chem; 2003 Sep; 278(37):35749-54. PubMed ID: 12837749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
    Mehta A; Sequiera GL; Ramachandra CJ; Sudibyo Y; Chung Y; Sheng J; Wong KY; Tan TH; Wong P; Liew R; Shim W
    Cardiovasc Res; 2014 Jun; 102(3):497-506. PubMed ID: 24623279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel characteristics of a trafficking-defective G572R-hERG channel linked to hereditary long QT syndrome.
    Lian J; Huang N; Zhou J; Ge S; Huang X; Huo J; Liu L; Xu W; Zhang S; Yang X; Zhou J; Huang C
    Can J Cardiol; 2010 Oct; 26(8):417-22. PubMed ID: 20931094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
    McBride CM; Smith AM; Smith JL; Reloj AR; Velasco EJ; Powell J; Elayi CS; Bartos DC; Burgess DE; Delisle BP
    J Membr Biol; 2013 May; 246(5):355-64. PubMed ID: 23546015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R534C mutation in hERG causes a trafficking defect in iPSC-derived cardiomyocytes from patients with type 2 long QT syndrome.
    Mesquita FCP; Arantes PC; Kasai-Brunswick TH; Araujo DS; Gubert F; Monnerat G; Silva Dos Santos D; Neiman G; Leitão IC; Barbosa RAQ; Coutinho JL; Vaz IM; Dos Santos MN; Borgonovo T; Cruz FES; Miriuka S; Medei EH; Campos de Carvalho AC; Carvalho AB
    Sci Rep; 2019 Dec; 9(1):19203. PubMed ID: 31844156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.